RAPP vs RZLT
RAPP: Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex neurological and psychiatric disorders. RZLT: Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
Side-by-side fundamentals
| Metric | RAPP | RZLT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $41.33 | $5.00 | |
| Market cap as of 2026-07-23 | $2.1B | $481M | |
| PEG as of 2026-07-23 | -0.90 | n/a | |
| ROE as of 2026-07-23 | -24.8% | -58.8% | RAPP higher |
| ROA as of 2026-07-23 | -23.4% | -54.5% | RAPP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 2.58 | 0.58 | |
| 1-year return as of 2026-07-22 close | +195.8% | -6.9% | RAPP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.